Overview

Multicenter Study Comparing Taxotere Plus Curcumin Versus Taxotere Plus Placebo Combination in First-line Treatment of Prostate Cancer Metastatic Castration Resistant (CURTAXEL)

Status:
Terminated

Trial end date:
2018-04-01

Target enrollment:

Participant gender:

Summary

Multicenter randomized phase II study, double-blind, comparing Taxotere plus curcumin versus Taxotere plus placebo combination in first-line treatment of prostate cancer metastatic castration resistant. Assess time to progression (time to progression) of metastatic disease (from first day of treatment in the trial).

Phase:

Phase 2

Details

Lead Sponsor:

Centre Jean Perrin

Treatments:

Curcumin
Docetaxel